May 16, 2018 / 1:13 PM / 6 months ago

BRIEF-Amgen Receives European Commission Approval For Repatha (Evolocumab)

May 16 (Reuters) - Amgen Inc:

* AMGEN RECEIVES EUROPEAN COMMISSION APPROVAL FOR REPATHA® (EVOLOCUMAB) TO PREVENT HEART ATTACK AND STROKE IN ADULTS WITH ESTABLISHED CARDIOVASCULAR DISEASE

* AMGEN INC - EC APPROVED A NEW INDICATION IN REPATHA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below